Preoperative NT-proBNP independently predicts outcome in patients with acute coronary syndrome undergoing CABG
2013 (English)In: Scandinavian Cardiovascular Journal, ISSN 1401-7431, Vol. 47, no 1, 28-35 p.Article in journal (Refereed) Published
Objectives. The predictive value of preoperative N-terminal pro-B-type natriuretic peptide (NT-proBNP) was evaluated in patients with acute coronary syndrome undergoing coronary artery bypass grafting (CABG). Design. As a substudy to a clinical trial 383 patients with acute coronary syndrome undergoing CABG were studied. 17 patients had a concomitant procedure. NT-proBNP was measured immediately preoperatively and evaluated with regard to in-hospital mortality, and severe circulatory failure postoperatively according to prespecified criteria. Follow-up was 3.2 +/- 0.9 years. Results. In patients with isolated CABG, receiver operating characteristics (ROC) analysis showed an area under the curve (AUC) of 0.82 for in-hospital mortality and 0.87 for severe circulatory failure respectively with a best cut-off for preoperative NT-proBNP of 1028 ng/L. This cut-off level independently predicted severe circulatory failure. Patients with NT-proBNP andlt; 1028 ng/L had significantly better long-term survival (p = 0.004). Preoperative NT-proBNP was higher in patients with concomitant procedure than isolated CABG (2146 +/- 1858 v 887 +/- 1635 ng/L; p = 0.0005). In patients with concomitant procedure ROC analysis showed an AUC of 0.93 for severe circulatory failure with a best cut-off for preoperative NT-proBNP of 3145 ng/L. Conclusions. Preoperative NT-proBNP predicted in-hospital mortality, severe circulatory failure postoperatively and long-term survival in patients undergoing surgery for acute coronary syndrome but a higher threshold was found in patients having concomitant procedures.
Place, publisher, year, edition, pages
Informa Healthcare , 2013. Vol. 47, no 1, 28-35 p.
acute coronary syndrome, coronary artery bypass grafting, natriuretic peptides
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-88661DOI: 10.3109/14017431.2012.731518ISI: 000313678500004OAI: oai:DiVA.org:liu-88661DiVA: diva2:605499
Funding Agencies|Swedish Heart-Lung Foundation|20030595|Capio Research Foundation|2005-10212006-1203|Linkoping University||Ostergotlands Lans Landsting||2013-02-142013-02-142013-11-19Bibliographically approved